Overview

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Status:
Completed

Trial end date:
2019-10-14

Target enrollment:

Participant gender:

Summary

This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

ONO Pharmaceutical Co.
Ono Pharmaceutical Co. Ltd

Treatments:

Antibodies, Monoclonal
Cetuximab
Cisplatin
Nivolumab